NBC News

FDA Grants Orphan Drug Designation to Aegerion Pharmaceuticals' Drug Candidate, Lomitapide, for Treatment of Familial Chylomicronemia

Lomitapide, in Phase III Development, Holds Orphan Drug Status for Treatment of CAMBRIDGE, Mass., March 15, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging ...
Healio

Olezarsen may not prevent coronary plaque progression, despite cutting triglycerides

Monthly olezarsen reduced triglycerides and apolipoprotein B in patients with hypertriglyceridemia but may have no impact on ...
Monthly Prescribing Reference

Olezarsen Cuts Triglyceride Levels in Patients With Familial Chylomicronemia Syndrome

Credit: Getty Images. In FCS, mutations in the lipoprotein lipase gene lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia. Treatment with olezarsen ...
Monthly Prescribing Reference

Tryngolza Approved for Familial Chylomicronemia Syndrome

Credit: Ionis Tryngolza is an apoC-III-directed antisense oligonucleotide that is administered subcutaneously once monthly. As an adjunct to a low fat diet, Tryngolza significantly reduced fasting ...
Nasdaq

TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet

CARLSBAD, Calif., Dec. 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (olezarsen) as an ...
Healio

Evinacumab shows benefit in certain patients with severe hypertriglyceridemia

Please provide your email address to receive an email when new articles are posted on . The reductions after treatment with evinacumab (Evkeeza, Regeneron) were evident in certain patients from two ...
Nasdaq

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) ...

EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

Sobi® (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indication extension application for Tryngolza® (olezarsen) for the treatment of adult patients with severe ...